Patent application number | Description | Published |
20090120686 | Electric Power Terminal Feed-Through - A power terminal feed-through incorporates a metallic body through which extend one or more current conducting pins that are hermetically sealed to the metallic body by a glass-to-metal seal. The metallic body includes an annular lip with a protrusion. During welding installation of the power terminal feed-through, the protrusion serves to assist in the welding process, better controlling the location and definition of the weld between the metallic body and a housing, and to focus the welding heat at the protrusion, thereby protecting the glass-to-metal seal. The glass-to-metal seal can be a single glass insert through which the current conducting pins extend, thereby reducing the pin circle diameter and the overall size of the power terminal feed-through. | 05-14-2009 |
20130196528 | CONNECTOR BLOCK WITH PARALLEL ELECTRICAL CONNECTION - An external connector block that can be positioned over multiple standard-sized power supply terminals that are secured to the housing of, e.g., a compressor is disclosed. The connector block includes an electrically conductive bridge connecting respective pins of the terminals in parallel. By connecting the terminals in parallel, the connector block increases the maximum allowable operating current of a terminal connection, while still utilizing standard-sized power terminal feed-throughs. As such, the connector block of the present disclosure may enable higher power rated applications without requiring a new power supply terminal design. | 08-01-2013 |
20140045355 | HERMETIC TERMINAL HAVING PIN-ISOLATING FEATURE - A hermetic terminal is disclosed as having a body including an exterior surface and a plurality of openings in the body accommodating a pin extending through each opening that is hermetically sealed and electrically isolated from the body. The terminal also includes a dielectric pin-isolating feature forming a barrier that increases the operative through-air spacing between the pins of the terminal. The power rating for the terminal is thereby increased without increasing the overall size of the terminal. | 02-13-2014 |
20140045369 | Hermetic Terminal With Fully Insulated Direct Wire Connection - A hermetic terminal assembly includes a terminal body and terminal pins extending through the terminal body. The terminal pins each have a first end configured for connection to a power source disposed outside of a hermetic compressor and a second end configured for direct connection to motor windings disposed within hermetic compressor. | 02-13-2014 |
Patent application number | Description | Published |
20110172398 | BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY - Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a Dll4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and Dll4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same. | 07-14-2011 |
20110195494 | DLL4-BINGING MOLECULES - DII4-binding molecules, preferably DII4-binding immunoglobulin single variable domains like VHHs and VHs, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with DII4-mediated effects on angiogenesis. Bispecific DII4-binding molecules that also bind to VEGF-A. Nucleic acids encoding DII4-binding molecules, host cells and methods for preparing same. | 08-11-2011 |
20110318366 | BIOLOGIC COMPOUNDS - The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders. | 12-29-2011 |
20120225081 | VEGF-BINDING MOLECULES - VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same. | 09-06-2012 |
20140120095 | BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY - Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a DII4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and DII4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same. | 05-01-2014 |
Patent application number | Description | Published |
20080267949 | Peptides capable of binding to serum proteins - The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs. | 10-30-2008 |
20090286727 | DP-78-Like Nanobodies - The present invention relates to Nanobodies® that have a high degree of sequence homology with human variable domain sequences from the V | 11-19-2009 |
20090297535 | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling - The present invention relates to amino acid sequences that are directed against interleukin-6 (IL-6), as well as to compounds or constructs, and in particular proteins and polypeptides that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 12-03-2009 |
20100215664 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH IL-6 -MEDIATED SIGNALLING - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 08-26-2010 |
20110059101 | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling - The present invention relates to amino acid sequences that are directed against interleukin-6 (IL-6), as well as to compounds or constructs, and in particular proteins and polypeptides that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 03-10-2011 |
20140314743 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL17-A/F AND POLYPEPTIDES COMPRISING THE SAME - The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 10-23-2014 |
Patent application number | Description | Published |
20120077731 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, to methods for preparing such amino acid sequences and polypeptides, to host cells expressing or capable of expressing such amino acid sequences or polypeptides, to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells, and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 03-29-2012 |
20140221623 | INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 08-07-2014 |
20140329278 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 11-06-2014 |
20140343257 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 11-20-2014 |
20140348830 | INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 11-27-2014 |
20140349342 | INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 11-27-2014 |
20150037338 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 02-05-2015 |